local_hospital
verifiedVerified

Neurocor Banaszkiewicz Tomaszewski Lekarze sp.p.

Address
Ul. Mieczyslawa Medweckiego 7/u12, 31-870 Krakow, Poland

Neurocor Banaszkiewicz Tomaszewski Lekarze sp.p. - Neurology Research Center

Neurocor Banaszkiewicz Tomaszewski Lekarze sp.p. is a specialized clinical research center dedicated to advancing treatments for complex neurological conditions. The center demonstrates particular expertise in conducting Phase III trials for both neurodegenerative diseases and neuromuscular disorders, with a strong focus on evaluating innovative therapeutic approaches that address unmet medical needs in neurology.

  • Neuromuscular disorders, including generalized Myasthenia Gravis
  • Neurodegenerative diseases, with emphasis on Alzheimer's disease and Parkinson's disease
  • Headache disorders, including chronic and episodic migraine prevention
  • Motor fluctuations and movement disorders in advanced Parkinson's disease

The center's research portfolio encompasses diverse therapeutic modalities, from botulinum toxin injections for migraine prevention to complement inhibitors for autoimmune conditions and novel formulations of levodopa/carbidopa for motor complications. With experience in evaluating treatments for cognitive impairment associated with Alzheimer's disease and addressing complex quality of life measures in Myasthenia Gravis, the center plays a vital role in bringing innovative neurological therapies from clinical development to patient care.

Site Overview

assignment
8
connected trials
corporate_fare
7
sponsors
science
9
IMPs

Activity Indicator

Last 6 months

2
Trials started
-33% vs previous period.
3
Trials started 6–12 months ago
8
Total trials linked
Active
trending_downDeclining-33%
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
7
Sponsors (total)
7
Active sponsors
6

Sponsor Network

Top 6 by active trials.

lock +5 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
8
Outperforms 75% of sites
public
Therapeutic diversity
2areas
Outperforms 53% of sites
groups
Sponsor diversity
7sponsors
Outperforms 77% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Neurocor Banaszkiewicz Tomaszewski Lekarze sp.p.

lock Showing 1 of 8 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Randomized, Double-Blind, Placebo-Controlled Study of AUR200 in Generalized Myasthenia GravisAurinia Pharmaceuticals Inc.Phase IRecruitingJun 2026

IMP list

lock Showing 1 of 9 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins2Unknown2025-10-062025-10-06

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.